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Remaining a major healthcare concern with nearly 29 million confirmed cases
worldwide at the time of writing, novel severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) has caused more than 920 thousand deaths since its outbreak in China,
December 2019. First case of a person testing positive for SARS-CoV-2 infection within
the territory of the Republic of Latvia was registered on 2nd of March 2020, 9 days prior to
the pandemic declaration byWHO. Since then, more than 277,000 tests were carried out
confirming a total of 1,464 cases of coronavirus disease 2019 (COVID-19) in the country
as of 12th of September 2020. Rapidly reacting to the spread of the infection, an ongoing
sequencing campaign was started mid-March in collaboration with the local testing
laboratories, with an ultimate goal in sequencing as much local viral isolates as possible,
resulting in first full-length SARS-CoV-2 isolate genome sequences from the Baltics
region being made publicly available in early April. With 133 viral isolates representing
∼9.1% of the total COVID-19 cases during the “first coronavirus wave” in the country
(early March, 2020—mid-September, 2020) being completely sequenced as of today,
here, we provide a first report on the genetic diversity of Latvian SARS-CoV-2 isolates.
Keywords: Latvia, COVID-19, next-generation sequencing, genetic diversity, 2019-nCoV, HCoV-19, SARS-CoV-2
INTRODUCTION
Current novel coronavirus disease (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), which was formerly known as 2019 novel coronavirus
(2019-nCoV), and is often referred to as human coronavirus 2019 (hCoV-19), responsible for a
sudden rise in pneumonia cases in Wuhan, China, late December 2019, was preventively deemed
a Public Health Emergency of International Concern by WHO as early as 30th January, 2020
with only as few as 7,836 cases confirmed worldwide back then. With rapidly growing number
of confirmed positive cases throughout the world, SARS-CoV-2 quickly became arguably the most
sequenced virus in history with more than 100 thousand (14 September 2020) viral isolate near
complete genome sequences of high quality available publicly at the time of writing at GISAID
repository thanks to the unprecedented rate of collaborations between researchers and unpublished
data sharing with the goal of effectively tackling the novel disease (1, 2).
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Genome of SARS-CoV-2
First reported genomic sequence of SARS-CoV-2 was deduced
from a metagenomic RNA of bronchoalveolar lavage fluid
specimen sampled from a patient who worked at Wuhan seafood
market, where the epidemiological onset of human-to-human
transmission of a novel zoonotic coronavirus is thought to have
taken place (3), although evidence of an earlier contraction of
the disease that was not associated with the seafood market has
been documented, leading to the conclusion that the primary
spill-over event has taken place elsewhere (4, 5). The sequence
of a 29,903 base-long non-segmented positive-sense single-
stranded RNA molecule representing complete genome of the
aforementioned isolate Wuhan-Hu-1 was deposited in GenBank
(6) on 5th of January, 2020 and is now known as a SARS-
CoV-2 reference sequence available under accession numbers
NC_045512.2 or MN908947.3.
While viral family Coronaviridae, that comprises α/β/1/γ
coronavirus genera, representatives are somewhat unique in
comparison with most other RNA viruses in regards to their
large genome size of ∼30 kb, genomic organization of individual
species does not differ much among other lower taxa within
the family, while boasting variable number of open reading
frames. The genome of SARS-CoV-2 begins with a 265-base-
long 5′-UTR region starting with a leader sequence followed
by a 21,290-base-long ORF1ab, comprising about 70% of the
genome length, that translates into two polyproteins via −1
ribosomal frameshift and encodes 16 non-structural proteins
(nsp1–nsp16). The remaining part of the genome comprises
ORFs coding for structural and accessory proteins of unknown
function, sequentially: Spike glycoprotein (S), ORF3a, envelope
protein (E), membrane glycoprotein (M), ORF6, ORF7a, ORF7b,
ORF8, nucleocapsid phosphoprotein (N), ORF10, followed by 3′-
UTR ending in poly(A) tail. However, no evidence that would
support the expression of SARS-CoV-2 ORF10-encoded protein
of unknown function is yet found in the literature (7).
Possible Origins of SARS-CoV-2
SARS-CoV-2 is the seventh zoonotic human coronavirus
known up to date, and, along with SARS-CoV and MERS-
CoV, is considered to be highly pathogenic and more severe
compared with other, milder symptoms causing, community-
acquired human coronaviruses (HCoV-229E, HCoV-OC43,
HCoV-HKU1, and HCoV-NL63) (8).
Studies on the origin of novel coronavirus have revealed
that complete genomic sequence of SARS-CoV-2 suggests a
more close, although not a direct parental, ancestral relationship
with bat [∼96% overall nucleotide homology with RaTG13 (9)]
and pangolin coronaviruses [up to ∼92% homology, with S
protein ACE2 receptor binding domain amino acid sequence
being 97.4% identical to SARS-CoV-2 (10)], than to those of
humans (∼79 and ∼50% identity to SARS-CoV and MERS-
CoV, respectively (11)), and, while bats are already a long-time
acknowledged reservoir of SARS-CoV-like β-coronaviruses (12,
13), the assumption that pangolins can serve as a natural host
for CoVs has been made only recently before the emergence
of SARS-CoV-2 (14, 15). Although the current risk of animal-
human transmission of COVID-19 is considered low, a number
of felines (16), canines (17), and minks (18) worldwide have been
reported to be infected with SARS-CoV-2.
SARS-CoV-2 Isolate Classification
With a steadily growing number of complete SARS-CoV-2
genome sequences, early efforts to classify novel isolates based
on their genetic make-up have resulted in numerous proposals
of different SARS-CoV-2 isolate classification systems (19–21),
some of which (e.g., PANGOLIN lineages) are complementary.
However, with more than 100,000 of SARS-CoV-2 genome
sequences being available publicly as of now, ongoing efforts to
aid in the classification of newly sequenced viral isolates have
resulted in the general acceptance of GISAID’s team developed
SARS-CoV-2major clade and lineage nomenclature system based
on the specific combinations of 9 SARS-CoV-2 genetic markers
(2). In accordance with this system, SARS-CoV-2 isolates can
be classified in at least six distinct major clades, namely: S, L
(containing reference sequence Wuhan-Hu-1), V, G, GH, GR,
and O (other) isolate clades (Table 1).
Mid-September, 2020, the most represented cladesWorldwide
are GR, G, and GH, roughly corresponding to 34.92, 22.59, and
22.14% of total SARS-CoV-2 isolates, respectively. All three of
these clades are characterized by C241T base substitution in 5′-
UTR region, C3037T silent mutation in ORF1a and missense
A23403G mutation that causes aspartic acid at position 614 of
spike glycoprotein (S) to change to glycine (S-D614G), that is
associated with higher viral loads and, in turn, is hypothesized
to increase the infectivity of these genotypes, with isolates
bearing this mutation quickly becoming dominant ones in
various regions throughout the world (22–24). More recent
clades GR and GH are further distinguished from the ancestral
G genotype by G25563T mutation resulting in position 57
of ORF3a protein to change from glutamine to histidine for
clade GH, and G28882A that changes glycine at nucleocapsid
phosphoprotein (N) aa position 204 to arginine for clade GR.
While the exact effect of GH clade-defining G25563T change
in apoptosis-inducing transmembrane ORF3a protein (Q57R)
remains unknown, it does not seem to affect any of the conserved
functional domains distinguishable within the protein (25, 26).
Whereas, G28882A mutation associated with GR genotype is
almost always a trinucleotide mutation of neighboring loci
resulting in GGG to AAC change at positions 28881, 28882,
and 28883, respectively. This trinucleotide mutation results in
two (R203K and G204R) consecutive amino acid changes in
N protein, which, in turn, might have potential implications
on nucleocapsid phosphoprotein structure and/or function via
reduction of conformational entropy and changes in inter-
residue interactions in the proximity of the mutated amino
acid positions [elaborated on in (27)]. The currently estimated
evolutionary rate of SARS-CoV-2 is around 9.86 × 10−4 to 1.85
× 10−3 substitutions per position per year (28), and, based on the
isolates sequenced worldwide up to date, there is evidence that
mutations in nearly every position in the genome of SARS-CoV-2
have already been documented (29).
In this study, we are reporting the first results of an ongoing
massive sequencing campaign that allows us to elaborate on the
genetic diversity of SARS-CoV-2 isolates from Latvian patients.
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TABLE 1 | Major SARS-CoV-2 clades defining genetic markers and their occurrence in Latvia, Europe, and Worldwide (as of 14 September 2020).
Clade genetic markers (n = 100272) (n = 52641)









S C C A T G G G C G 5.79 2.82 0
L C C A C G G G T G 4.31 5.78 3.01
V C C A C T G T T G 5.16 8.46 0
G T T G C G G G T G 22.59 28.54 16.54
GH T T G C G T G T G 22.14 10.56 30.83
GR T T G C G G G T A 34.92 41.79 48.12
Other X X X X X X X X X 5.09 2.05 1.5
X denotes any nucleotide.
MATERIALS AND METHODS
Sample Management and Detection of
SARS-CoV-2
For viral genome analysis, either oropharyngeal or
nasopharyngeal swabs obtained from COVID-19 patients
or already extracted RNA samples were provided to Latvian
Biomedical Research and Study Center by the three accredited
diagnostic laboratories (E. Gulbis Laboratory, Central Laboratory
and Latvian Center of Infectious Diseases) covering diagnostics
of all officially reported cases of SARS-CoV-2. RNA extraction
from oropharyngeal and nasopharyngeal swabs and the
following SARS-CoV-2 detection was performed by multiple
different methods according to standard procedures of each
laboratory. These included manual Trizol-based RNA extraction
(TRI reagent, Sigma) and automated purification methods
with STARMag 96 X 4 Universal Cartridge Kit (Seegene Inc.),
NucliSENS easyMAG (bioMérieux), QIAamp 96 Virus QIAcube
HT Kit (QIAGEN). The presence of SARS-CoV-2 in the
purified RNA samples for the diagnostics was estimated by,
either commercial (Allplex
TM
2019-nCoV Assay, Seegene Inc,
detecting the E, RdRp and N genes according to manufacturer
instructions) or in-house RT-qPCR methods (detecting the N
and S genes) (30), or even both to ensure the technical validation
of the obtained test results. Samples showing amplification (ct
<40) of at least one viral gene (RdRp, E, N) were considered
positive and directed to next-generation sequencing.
Next-Generation Sequencing Approach
Selection
Metatranscriptome sequencing was the first-choice method
for the SARS-CoV-2 genome analysis. Nevertheless, since the
majority of samples showed an insufficient number of sequencing
reads mapping to the SARS-CoV-2 genome and could not
be reliably analyzed, targeted sequencing approaches were
considered. A methodological strategy plan was developed in
order to apply the most effective next-generation sequencing
method for each sample according to the quantity of SARS-CoV-
2 (Supplementary Figure 1). At first, RT-qPCR was repeated for
each sample in order to evaluate the quantity of viral RNA with a
common approach for all samples. Three SARS-CoV-2 genome-
specific primer pairs and probes targeting different regions of the
nucleocapsid protein (N) gene implemented in the 2019-nCoV
RUO Kit (IDT) and SOLIScript R© 1-step CoV Kit (Solis Biodyne)
were used for the amplification (Supplementary Table 3). Probes
N1 and N2 specifically detected SARS-CoV-2, while the N3
probe universally detected all currently recognized clade 2 and
3 viruses within the subgenus Sarbecovirus (31). To evaluate the
RNA extraction and PCR efficiency, simultaneous amplification
of the human RNase P gene was performed and a control sample
containing a plasmid with the SARS-CoV-2 nucleoplasmid
protein gene (2019-nCoV_N_Positive Control, IDT) was added
to each reaction set. The potential contamination was evaluated
by a negative control (nuclease-free water instead of RNA)
added to each sample set. RT-qPCR was conducted on the
ViiA 7 Real-Time PCR System (Thermo Fisher Scientific), and
only the samples showing amplification (ct <40) of all three
SARS-CoV-2 nucleoplasmid protein genes were further directed
to metatranscriptome sequencing. Samples exhibiting poor
amplification of viral genes (ct >40 for at least one target region)
were considered for one of targeted sequencing approaches:
hybridization capture or amplification of SARS-CoV-2.
Metatranscriptome Sequencing
In order to eliminate contaminating DNA, DNase I treatment
(NEB) of RNA samples was performed, followed by rRNA
depletion with MGIEasy rRNA Depletion Kit (MGI Tech
Co. Ltd). Complementary DNA libraries were prepared using
MGIEasy RNA Library Prep Set (MGI Tech Co. Ltd). Quantity
and quality of both RNA and cDNA were evaluated using
the Qubit 2.0 fluorometer and Agilent 2100 Bioanalyzer
system, respectively. The presence of the SARS-CoV-2 genome
was repeatedly tested in each cDNA library by Q-PCR
before sequencing, using the same primers and probes (2019-
nCoV_N_Positive Control, IDT) together with TaqMan
TM
Gene Expression Master Mix (Thermo Fisher Scientific). After
multiple experimental tests, a ct value threshold of 25 was
chosen for N1 and N3 probes for cDNA libraries to be
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forwarded to metatranscriptome sequencing (N2 probe appeared
to be unstable and therefore uninformative). Metatranscriptome
cDNA libraries were sequenced on the DNBSEQ-G400RS
sequencing platform with DNBSEQ-G400RS High-throughput
Sequencing Set (PE150) (MGI Tech Co. Ltd), obtaining at
least 100 million 150-bp-paired-end sequencing reads per
each sample. Those libraries that failed to pass the ct
threshold (ct >25 for N1 and N3) were directed to a
targeted approach.
SARS-CoV-2 Hybridization Capture
One of the targeted sequencing strategies was based on the
enrichment of the SARS-CoV-2 genome by hybridization probes.
For cDNA library preparation TruSeq Stranded Total RNA
Library Prep Gold kit and TruSeq RNA UD Indexes (Illumina)
were used. The indexed cDNA libraries were enriched for the
SARS-CoV-2 genome using compatible hybridization probes
implemented in the myBaits Expert SARS-CoV-2 kit (Arbor
Biosciences) according to manufacturers’ instructions. See the
official webpage of the manufacturer (https://arborbiosci.com/)
for the full list of hybridization probes used. The enriched
libraries were sequenced on Illumina MiSeq system with MiSeq
Reagent Kit v3 (150-cycle), obtaining at least 1 million of around
75-bp-paired-end reads per sample.
Amplification of SARS-CoV-2 Genome
The second targeted approach involved multiplexed primers
for amplification of the whole SARS-CoV-2 genome. QIAseq
SARS-CoV-2 Primer Panel (QIAGEN) based on the study
from the ARTIC network [https://github.com/artic-network/
artic-ncov2019, (32)] was used together with QIAseq FX DNA
Library Kit (QIAGEN) for cDNA library preparation. Next-
generation sequencing was performed on Illumina MiSeq system
with MiSeq Reagent Kit v2 (300-cycles), obtaining at least 1
million of around 150bp paired-end reads per sample.
Sequencing Data Quality Control, Variant
Calling, and Data Sharing
Adapter clipping was performed with cutadapt 1.16 (33).
Subsequent read trimming was performed with fastp 0.20.0 (34)
using five base-sliding window trimming from both ends with
quality threshold 20. Reads with length <75 bp or an average
quality of <20 were removed. Quality-controlled reads were
then aligned against SARS-CoV-2 isolate Wuhan-Hu-1 reference
genome (Accession number: NC_045512.2) with bowtie2 2.3.5.1
(35). Variant calling and consensus sequence construction were
implemented using bcftools 1.10.2 (36). Average coverage for
each of the genomes was calculated using samtools and in-
house awk (37, 38) scripts. Less than 1% of the missing
bases were allowed for a genome to be considered successfully
sequenced and missing bases were treated as reference bases
from the Wuhan-Hu-1 genome. Consensus sequences of the
successfully sequenced isolates were then proceeded to the
manual variant quality inspection by sequence alignment map
visualization in IGV (39), sequences that have passed the manual
variant quality check were immediately publicly shared by
deposition to GISAID database (2). Variant annotations were
performed using coronapp SARS-CoV-2 genome autoannotation
web server by comparisons to reference sequence (40) and
the results were summarized with the help of custom R
scripts, ggplot2 R library was used for plot visualizations
(41, 42).
Phylogenetic Reconstructions
The dataset (alignment of 133 Latvian SARS-CoV-2 isolates and
Wuhan-Hu-1 reference sequence) was tested for the presence
of a phylogenetic signal prior to our phylogenetic analyses
by the likelihood mapping analysis implemented in IQTREE
version 2.0.6 (using 1,000× number of samples (134,000)
randomly drawn quartets) (Supplementary Figure 4) (43, 44).
Sequences of the Latvian SARS-CoV-2 isolates andWuhan-Hu-1
reference sequence were aligned using Clustal-Omega v1.2.4 (45).
Maximum likelihood phylogeny was performed using IQTREE
v2.0.6 (44) with GTR+F+I as best fit model determined by
ModelFinder (46) according to Bayesian Information Criterion
[ultrafast bootstrap with 1,000 replicates (47)] and assessment
of temporal signal associated with the data was performed
by importing resulting ML tree into TempEst v1.5.3 (48),
parsing sampling dates of isolates and visualizing the root-to-
tip divergence.
Bayesian phylogenetic trees were estimated using BEAST
v1.10.4 (49), employing GTR nucleotide substitution model
with empirical base frequencies and invariant site proportion
assuming strict molecular clock. Coalescent exponential growth
prior (growth rate prior: Laplace with scale 100; population
size prior: Lognormal with mu 1 and sigma 2) with growth
rate parametrization (50, 51) was selected and Markov chain
Monte Carlo (MCMC) was run for 50 million states sampling
log parameters and trees every 5,000 states. Tracer v1.7.1 (52)
was used for MCMC trace (log file) inspection to evaluate
sufficiency of sampling (all parameters had an ESS of more
than 400) and infer substitution rate along with the date of the
most recent common ancestor estimate. To summarize Bayesian
phylogenetic inference, maximum clade credibility time-scaled
tree was generated in TreeAnnotator v1.10.4 (distributed with
BEAST package) using 10% of the states (5million) as the burn-in
and visualized using FigTree v1.4.4 (53).
RESULTS AND DISCUSSION
With 1,464 cumulative positive cases as of 12th of September
2020 (1,248 people recovered, 181 active cases of the disease,
and 35 COVID-19-associated deaths), 133 SARS-CoV-2 isolates
representing ∼9.1% of the total local COVID-19 cases have
been completely sequenced as of today, making Latvia one of
the leading countries not only in regards to the containment
of the spread of COVID-19 disease, but in the number of
sequenced SARS-CoV-2 isolates to the cumulative number of
positive COVID-19 cases ratio as well (Figure 1).
Reacting to the emergence of the SARS-CoV-2 in Latvia, a
high-throughput framework for SARS-CoV-2 isolate sequencing
and data analysis with capabilities of near real-time tracking
of the epidemiological situation in Latvia was built to aid
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FIGURE 1 | Daily numbers of positive COVID-19 cases (A) and tests performed (B) in Latvia. x-axis is the same for both tiles and represents daily time series from
28th of February, 2020 to 11th of September, 2020. The red vertical line indicates the date of the first COVID-19 case registered in Latvia. (A) Y value represents the
total number of positive cases registered on a given day. Blue area shows the number of only successfully sequenced isolates, while the red area represents the
positive cases not sequenced during this study. (B) Y value represents the number of tests carried out on a given date in Latvia.
the governmental decision-making and study the molecular
epidemiology of hCoV-19.
One of the challenges to obtain good-quality sequences for
maximal number of samples is the variable quality of input
material that can be caused by highly variable viral loads, different
collection, storage and RNA isolation methods. Although for
the current study we did not have the information on the
severity of COVID-19 symptoms for particular cases, it should
be noted that the absolute majority of cases in Latvia are with low
symptom severity expected to have lower concentration of virus
in diagnostic samples. We therefore developed an approach to
verify sample quality and select appropriate sequencing method
to recover maximal available information from existing samples
ensuring cost efficacy of the process (Supplementary Figure 1).
According to this strategy developed during the implementation
of the study, complete SARS-CoV-2 genome sequence was
successfully obtained by metatranscriptome approach for 37
viral isolates, 80 samples were analyzed by amplification of
SARS-CoV-2 genome with multiplexed primers, and for 16
isolates enrichment of SARS-CoV-2 genome was performed by
hybridization capture method prior the sequencing.
As of now, it could be cautiously speculated that the obtained
results on the SARS-CoV-2 genotype distributions might be
somewhat representative of a whole Baltics region, taking the
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geographical proximity, travel habits, and mild governmental
travel regulations between the Baltic states during the most
of the pandemic into the account. However, the extent of
similarity between the isolates circulating in different Baltic
states currently cannot be reliably established due to SARS-
CoV-2 isolate undersequencing in neighboring Estonia and
Lithuania, and the founder effect of multiple independent (re-
)introductions of different SARS-CoV-2 genotypes, as well as
containment effectivity of respective COVID-19 cases, in each of
the countries should not be overlooked.
Distribution of Sequenced Virus Isolates by
SARS-CoV-2 Clades
Major isolate clade distributions across distinct geographical
regions show clear spatial differences of the epidemic (Figure 2)
and a trend of “older” isolate clades L and S losing their initial
prevalence to the dominance of the more recently emerged G-
associated clades (G, GH, GR) that seem to be accountable for the
majority of the cases worldwide since the middle of March 2020.
GR, which is the most common isolate clade in Latvia (48.12%
of cases), is also a dominant clade in Europe and South America.
Currently, GH still seems to be the most common isolate clade
circulating throughout North America, but a rise in the number
of GR isolates can be observed since the middle of May 2020.
The prevalence of GR and, in particular, G clade isolates is also
currently on the rise in Africa, and, to a very moderate amount
in Oceania and Asia. The relatively high number of isolates not
corresponding to any of the currently recognized major SARS-
CoV-2 clades (dubbed “Other” or belonging to the “O” clade as
of now) in Asia and Oceania makes it possible to speculate about
it being indicative of either (but not mutually exclusive), poor
quality of the sequences obtained or the possibility of novel clade
emergence originating from these regions in the future, should
their spread not be effectively contained.
Mutational Landscape of Latvian
SARS-CoV-2 Isolates
After joining of the neighboring loci, among 133 local isolates,
247 different unique mutational events (154 non-synonymous,
84 synonymous, 7 substitutions in extragenic regions, single
deletion, and a single stop codon introduction) that affected 244
positions of the SARS-CoV-2 genomewere registered from a total
of 1,355 variants that were identified. One hundred forty-six out
of 247 distinct mutational events were registered only in one of
the 133 samples, while 101 were present in two or more samples
(Supplementary Table 1; Supplementary Figure 2). NSP3 was
found to be the mature peptide most frequently affected by non-
synonymous substitutions (24 distinct variants resulting in an
amino acid change), followed by an N protein that had 15 non-
synonymous SNVs documented among Latvian SARS-CoV-2
isolates. Among the most frequently mutated proteins, NSP2, S,
and NSP12b mature peptides harbored 13, 12, and 10 different
amino acid altering mutations, respectively.
Based on the current coronapp web-server [38] report
updated at 15 September 2020 (n = 89,978), most frequent
mutational events worldwide are as follows: A23403G
corresponding to S:D614G, C3037T silent mutation, C14408T
resulting in NSP12b:P314L, C241T extragenic substitution and
GGG28881ACC trinucleotide mutation of neighboring loci
resulting in N:RG203KR, G25563T—ORF3a:Q57H. All six of
these mutations were also among the most frequent mutational
events registered in Latvian samples: 5′-UTR C241T extragenic
substitution that was present in 129 out of 133 sequenced
genomes, while C3037T silent (NSP3:F106F) mutation, A23403G
(S:D614G), and C14408T (NSP12b:P314L) were all present in
128/133 samples, GGG28881AAC trinucleotide mutation
(N:RG203KR) was observed in 59/133 of the samples, and 28881
position of the genome had two more variants detectable in the
samples—GGGG28881AACT (N:RG203KL) quadranucleotide
mutation (32/133) and G28881A (N:R203K) substitution being
present in five of the samples, while G25563T—ORF3a:Q57Hwas
found in 41 of the isolates (see Table 2; Supplementary Table 1).
It was noted that five out of six aforementioned mutations
(with the exclusion of C14408T) are in the genome positions
serving as markers for current SARS-CoV-2 isolate major
clade definition and correspond to GR clade, that is the
most represented clade Worldwide and hosts almost half of
the sequenced isolates in Latvia (Tables 1, 2). The C14408T
substitution resulting in NSP12b:P314L amino acid change has
been previously reported to co-occur with C241T, C3037T, and
A23403G mutations (54), which is consistent with our data,
where four of these SNPs were simultaneously present 127/133
of the Latvian SARS-CoV-2 isolates sequenced up to date. While
no experimental evidence of C14408T substitution implications
on the NSP12b (RdRp) activity is yet present, isolates bearing
this variant were previously speculated to have more mutations,
and elaborations about possible implications of RdRp mutations
on antiviral drug resistance were made (55). The fitness of G
and G-derived strains, as denoted by the recent rise of their
prevalence throughout different regions of the world, is hardly
explainable only by the founder effect alone, thus highlighting the
fact that further evidence on molecular and clinical implications
of the most common substitutions in the genomes of currently
circulating SARS-CoV-2 is urgently needed to improve the
measures of containment of COVID-19 and develop effective
antiviral therapies and vaccines, that would help to not only
combat the present virus of immediate concern but also be of vital
importance for other coronaviruses to yet emerge.
Phylogenetic Analyses
Likelihood mapping analysis conducted to evaluate the presence
of phylogenetic signal suggested that there, indeed, is a
phylogenetic signal in our dataset (Supplementary Figure 4,
<1/3 of the quartets unresolved, 64.68% of quartets fully
resolved). Root-to-tip regression analysis with the “best-
fitting root” and “correlation” function options resulted
in a correlation coefficient of the analysis being estimated
at 0.6754 and a determination coefficient (R2) equaling
to 0.4562 (Supplementary Figure 3). Although having
some of the sequences that diverged more or less than
expected at their sampling date, the dataset had a moderate
association between sequence divergence and sampling
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FIGURE 2 | Distribution of sequenced SARS-CoV-2 isolates by clades in major regions of the world, worldwide, and in Latvia. y-axis depicts cumulative complete
SARS-CoV-2 genome count (with unambiguous collection date) from a particular region and has different scale within the subplots. x-axis is the same for all subplots
and depicts sampling time-series from 24th of December, 2019 till 12th of September, 2020.
date, implying suitability for phylogenetic molecular
clock analysis.
Following Bayesian phylogenetic inference, mean
evolutionary rate derived from Latvian SARS-CoV-2 isolates was
found to be 7.5185× 10−4 substitutions per site per year (6.0256
× 10−4-9.1308 × 10−4, 95% highest posterior density interval),
roughly corresponding to an average of 22–23 mutational events
in genome per year (95% HPD: ∼18 to ∼27), and lies within
or close to the evolutionary rate ranges predicted by other
researchers (56–59). Based on the analysis, the estimated most
recent common ancestor of the isolates has emerged on 16th
of November, 2019 (4th October, 2019–27th December, 2019,
95% interval). Our molecular clock analysis (Figure 3) further
supported the more recent divergence of G and G-derived
(GR and GH) clades with the most recent common ancestor
for three of the aforementioned major clades dating back to
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TABLE 2 | Ten most frequently mutated genome positions among Latvian SARS-CoV-2 isolates (n = 133).
Position in
genome










241 C 5′UTR:241 T Extragenic 5′UTR 241 N/A 129 96.99%









23,403 A S:D614G G SNP S D614G Spike 128 96.24%
GGG N:RG203KR AAC RG203KR 59 44.36%
28,881 G N:R203K A SNP* N R203K Nucleocapsid protein 32 96 24.06% 72.18%
GGGG N:RG203KL AACT RG203KL 5 3.76%
25,563 G ORF3a:Q57H T SNP ORF3a Q57H ORF3a protein 41 30.83%
18,877 C NSP14:C279C T Silent NSP14 C279C 3′-to-5′ exonuclease 36 27.07%
1,202 A NSP2:N133D G SNP NSP2 N133D Non-Structural protein
2
34 25.56%
12,513 C NSP8:T141M T SNP NSP8 T141M Non-Structural Protein
8
34 25.56%
25,710 C ORF3a:L106L T Silent ORF3a L106L ORF3a protein 33 24.81%
Color coding is based on the variant class, as follows: red represents extragenic variants; green, silent variants; and blue, single nucleotide polymorphisms. Asterisk (*) in “Variant class”
column represents that there are multiple variants present at a given genome position (28,881); some of them are neighboring loci polynucleotide variants rather than SNP.
6th of January, 2020 (95% HPD: 27th November, 2019–5th
February, 2020) and allowed us to date the near-simultaneous
emergence of TMRCAs for clades GR (8th of February, 2020;
95% HPD: 16th January, 2020–28th of February, 2020) and
GH (10th of February, 2020; 95% HPD: 17th January, 2020–1st
March, 2020). The 95% HPD date ranges are consistent with the
collection dates of unambiguously dated genomes belonging to
clades GH and GR deposited at GISAID (accessed 14 August
2020). Earliest reported SARS-CoV-2 genome belonging to clade
GH was collected on 2nd of February 2020 in Riyadh, Saudi
Arabia (GISAID accession: EPI_ISL_489996), while earliest
reported GR clade genome was collected on 16th of February
2020 in London, England (GISAID accession: EPI_ISL_466615),
however first reported sequences with unambiguous collection
date belonging to GR and GH ancestral clade G were collected on
24th of January, 2020, in China, cities of Zhejiang and Chengdu
(GISAID accessions: EPI_ISL_422425, EPI_ISL_451345).
Our phylogenetic analysis of the local isolates suggests
multiple unlinked initial introductions of already divergent
SARS-CoV-2 isolates to Latvia. Just 2 weeks after the first
positive case of COVID-19 was documented in Latvia on the
2nd of March, isolates representing at least three major SARS-
CoV-2 clades (L, GR, and GH) were already circulating within
the country corresponding to at least four epidemiologically
unlinked introductions. No isolates belonging to clade L (most
similar to the initial Wuhan-Hu-1 reference) were sequenced
after the end of March and local circulation of clade G
representatives was not detectable until the end of August, while
clade GH and, specifically, GR isolates seem to have taken hold
of the epidemic without showing any signs of ceasing their
proliferation within the Latvian population; however, recent
reintroduction event possibility should not be ruled out due
to cancelation of travel restrictions and insufficient testing of
those entering the country. With nearly half of the sequenced
isolates belonging to the widely represented GR clade, up
to this date, no isolates representing clades V or S were
documented among the sequenced Latvian COVID-19 cases
(Figures 2, 3).
Maximum-likelihood phylogenetic tree was built to more
apparently infer genetic distances between the samples
(Figure 4). Although of satisfactory topology, supporting
major clade clustering, the tree evidently shows the possible
discrepancies between the reported sampling dates and expected
sequence divergence (e.g., some of the samples most divergent
from the root are dated with the end of April, while some of
the most recently collected ones are notably less divergent),
which, we believe, after manually inspecting the sequence
alignment maps, is not attributable to sequencing errors
or the possibility of coinfection by two different “strains.”
Identical sequences sampled within a short date range (Figure 4)
might be strongly indicative of epidemiologically linked
transmission, given the relatively small daily amount of positive
COVID-19 cases in Latvia that never exceeded 48, even
during the “first wave” peaks of the disease spread up to late
September, 2020.
While providing interesting insights on the COVID-19
situation in Latvia during the so-called “first coronavirus wave”
(early March, 2020–mid-September, 2020), which might be
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FIGURE 3 | Maximum clade credibility tree (mean node heights) estimated from the completely sequenced Latvian isolates (n = 133) and Wuhan-Hu-1 isolate. Node
labels are colored according to the GISAID major clade of particular isolate, as follows: green, GR; yellow, GH; red, G; blue, L; purple, O (other); black, Wuhan-Hu-1
reference sequence. The tree is time scaled and axis represents time in a decimal year notation (1 months is ∼0.08333 of a year and 1 day is ∼0.00274 of a year).
Nodes are colored according to their respective posterior probabilities in gradient from blue (lowest value) to red (highest value). Dated node bars represent 95%
highest posterior density intervals and are shown for the selected nodes.
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FIGURE 4 | Evolutionary relationships of 133 sequenced Latvian and Wuhan-Hu-1 SARS-CoV-2 isolates. The evolutionary history was inferred using the
Maximum-likelihood method allowing for polytomies. The tree is rooted at Wuhan-Hu-1 reference sequence. The tree is drawn to scale; branch lengths correspond to
nucleotide substitutions. The analysis involved 134 nucleotide sequences (133 Latvian SARS-CoV-2 isolates and Wuhan-Hu-1 reference sequence). There were a
total of 29,903 positions in the final dataset. Node labels are colored according to the GISAID major clade of particular isolate, as follows: green, GR; yellow, GH; red,
G; blue, L; purple, O (other); black, Wuhan-Hu-1 reference sequence.
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representative of Baltics region to an extent, given the scarce
amount of isolate genomes available from neighboring countries,
it, however, should be noted, that the main drawback for
each of the presented analyses is stemming from the available
dataset—discrete early sampling with some of the dates since
first positive case not being sampled at all (Figure 1). Another
major drawback is the unavailability of complete patient/isolate
epidemiological data that could be linked to the respective
cases sequenced (e.g., sequence epidemiological linkage, patient
travel history, etc.), which could be used to further refine the
resolution of the analyses carried out, in the frame of this
study. As currently Latvia is forced to be facing the “second
coronavirus wave” that has not yet reached its peak, while the
total number of cases in the country has more than tripled
during month and a half since the middle of September,
inclusion of additional data and retrospective sequencing of
a larger number of cases that would allow for a more
complete and in-depth analysis of the epidemiological situation
throughout the whole epidemic in Latvia will be performed
as soon as COVID-19 will cease to be a relevant threat and
published elsewhere.
In conclusion, the high-throughput framework for SARS-
CoV-2 isolate sequencing and data analysis in Latvia has been
built by Latvian Biomedical Research and Study Center early on
during the start of the pandemic, tested with the help of both,
governmental and local private laboratory sample providers,
and proposed as a pivotal tool to monitor the local outbreaks
and aid in decision making. This framework has allowed us
to ensure the successful sequencing of viral isolates from the
majority of the new cases of epidemiological importance starting
from the beginning of July, 2020 with fast date delivery to the
Center for Disease Prevention and Control in Latvia allowing
to link the epidemiological data with the genetic makeup
of the priority isolates being sequenced and thus aiding the
epidemiological investigations. We believe that this framework
is of vital importance for rapid implementation of the most
suitable public health measures, possible transmission history
deduction, and viral evolution monitoring for the prevention of
future epidemiological outbreaks and, with 14-day cumulative
incidence reaching 2,202 as of 30th of October, 2020, is
currently facing its hopefully greatest challenge up to date
in the form of SARS-CoV-2 raging in Latvia with a whole
new force.
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